Bosch Rexroth is leading the charge in conveyance systems for robotics, integrating high-speed technologies and designs that are more efficient, flexible and precise for modern ...

Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.

The aim of this phase 3 study is to confirm the efficacy and safety of relacorilant + nab-paclitaxel in a larger population. Methods: ROSELLA (NCT05257408) is a randomized, controlled, open-label, ...

All three NBA legends have ties to Anthony. Iverson was traded to the Denver Nuggets in the 2006-07 season and was Anthony’s teammate for nearly three seasons, reaching the playoffs twice.

HARMONi-2 is an ongoing China phase 3 trial in first-line, PD-L1-positive NSCLC. The trial has met its PFS endpoint, with its overall survival data remaining immature.

The Employees Provident Fund Organisation (EPFO) will soon launch EPFO 3.0, a new digital platform offering features like automatic claim settlement, ATM withdrawals, and online corrections. This ...

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction ...

a Formal significance testing was only performed at 52 weeks in the Phase 3 trials, with significance achieved for both the every two-week arm and every four-week arm in AERIFY-1 . The total number of ...

Over 200 patients were dosed, and 365 enrolled in the Nex-Z MAGNITUDE trial, aiming for 765 by early 2027. Intellia plans BLA filing for NTLA-2002 in HAE by late 2026, with a U.S. launch targeted ...

ENLIGHTED phase 3 study: Interim results of efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) in the treatment of low-grade upper tract urothelial cancer (LG UTUC). This ...

As we prepare for the Phase 3 OVATION 3 Study, which will evaluate IMNN-001 in women with stage IIIC or IV ovarian cancer (randomized 1:1, with OS as the primary endpoint), ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the ...